復星醫藥(02196.HK):MPP授予復星醫藥產業使用相關專利技術生產口服新冠治療藥物
格隆匯3月18日丨復星醫藥(02196.HK)發佈公吿,MPP(即“藥品專利池組織”)授予公司控股子公司復星醫藥產業使用相關專利和專有技術生產口服新冠治療藥物“奈瑪特韋(Nirmatrelvir)”的仿製藥和許可產品“奈瑪特韋/利托那韋組合”,並在區域內(即印度、巴基斯坦、科特迪瓦等 95箇中低收入國家,不包括中國)商業化許可產品及相關權利的非獨家許可。上述生產包括對奈瑪特韋原料(藥)及成品藥(製劑)的生產,以及奈瑪特韋/利托那韋組合的生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.